MicroRNAs in metabolic effects with atypical antipsychotics—a scoping review
Therapeutic Advances in Psychopharmacology · 2026-03 · 16
DOI: 10.1177/20451253261430603 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 31.03.2026. Verfasst von Weng Tong Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Psychiatry and Mental Health, University of New South Wales Sydney, Sydney, NSW, Australia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolic side effects associated with atypical antipsychotics represent a major challenge in the clinical management of schizophrenia, contributing to poor treatment adherence and an increased risk of relapse. MicroRNAs (miRNAs) have emerged as promising diagnostic biomarkers for schizophrenia, with growing evidence indicating that their expression is modulated by antipsychotic treatment. Dysregulated miRNAs may not only reflect underlying disease mechanisms but also actively contribute to therapeutic response and the development of metabolic side effects.
Objectives
This scoping review critically evaluates the current literature on miRNAs in schizophrenia, focusing on their role in modulating treatment response and antipsychotic-induced metabolic disturbances. Key knowledge gaps are identified to inform future translational research. Eligibility criteria: We included studies involving adults or animal models with psychotic symptoms (with schizophrenia as the primary diagnosis) treated with atypical antipsychotics. Eligible studies reported associations between miRNA expression, metabolic parameters, and clinical outcomes. Sources of evidence: A rapid review was conducted using PubMed to identify relevant articles published up to December 1, 2025 and 16 articles were included for final review. Charting methods: Data charting was performed by one reviewer using a pre-developed and piloted form. The review was reported according to the Preferred Reporting items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR checklist).
Results
Atypical antipsychotics, particularly those acting on dopamine and serotonin receptors, were shown to modulate specific dysregulated miRNAs. Several of these miRNAs regulate genes involved in metabolic pathways, such as lipid and glucose metabolism, potentially contributing to the variability in cardiometabolic side effects observed across individuals.
Conclusion
Emerging evidence suggests that miRNAs may play a dual role in mediating both therapeutic efficacy and metabolic risk in schizophrenia treatment. However, the underlying mechanisms remain incompletely understood. Robust, large-scale studies are urgently needed to validate miRNAs as clinically actionable biomarkers for guiding personalized antipsychotic therapy.
Trial registration
A protocol was not prospectively registered, as the aim of this scoping review was exploratory in nature.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Discipline of Psychiatry and Mental Health, University of New South Wales Sydney, Sydney, NSW, Australia.
- School of Medicine, Western Sydney University, Sydney, NSW, Australia.
- Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.
- Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA.
- Discipline of Psychiatry and Mental Health, University of New South Wales Sydney, AGSM Level 3, Sydney, NSW 2052, Australia.
- Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO, USA.
ORCID-Profile: Weng Tong Wu, Ping-I Lin
Zitieren
APA
Wu, W. T., Setiawan, D., Glatt, S. J., Chi, J. T., & Lin, P. I. (2026). MicroRNAs in metabolic effects with atypical antipsychotics—a scoping review. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261430603
Vancouver
Wu WT, Setiawan D, Glatt SJ, Chi JT, Lin PI. MicroRNAs in metabolic effects with atypical antipsychotics—a scoping review. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261430603
BibTeX
@article{Wu2026,
author = {Wu, Weng Tong and Setiawan, Deonna and Glatt, Stephen J and Chi, Jen-Tsan and Lin, Ping-I},
title = {MicroRNAs in metabolic effects with atypical antipsychotics—a scoping review},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2026},
volume = {16},
doi = {10.1177/20451253261430603}
}
EUVIMED